We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
  • Patient Resources
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
    • Glossary
  • Professional Resources
    • Research Center Profiles
    • Industry Provider Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
  • About Us
  • Contact Us
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Ampyra (dalfampridine)

  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Ampyra (dalfampridine)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Ampyra (dalfampridine) is a potassium channel blocker that enhances conduction in damaged nerves. The exact mechanism by which dalfampridine exerts its therapeutic effect has not been fully elucidated.

    Ampyra is specifically inidicated as a treatment to improve walking in patients with multiple sclerosis.

    Ampyra is supplied as an extended release tablet for oral administration. The maximum recommended dose of Ampyra is one 10 mg tablet twice daily, taken with or without food, and should not be exceeded. Doses should be taken approximately 12 hours apart. Patients should not take double or extra doses if a dose is missed.

    Clinical Results

    FDA Approval
    The FDA approval of Ampyra was based on two clinical trials.
    Trial One
    This randomized, placebo-controlled, parallel group, 21-week study enrolled 301 patients with multiple sclerosis at 33 centers in the U.S. and Canada. The patients were assigned to Ampyra 10 mg twice daily or placebo. A total of 283 subjects completed the study. The primary measure of efficacy was walking speed (in feet per second) as measured by the Timed 25-foot Walk (T25W), using a responder analysis. A significantly greater proportion of patients taking Ampyra were responders compared to patients taking placebo: 34.8% vs. 8.3%, respectively. The increased response rate was observed across all four major types of MS disease course. During the double-blind treatment period, a significantly greater proportion of patients taking Ampyra 10 mg twice daily had increases in walking speed of at least 10%, 20%, or 30% from baseline, compared to placebo.
    Trial Two
    This randomized, placebo-controlled, parallel group, 14-week study enrolled 239 patients with multiple sclerosis at 39 centers in the U.S. and Canada. The subjects were assigned to 10 mg twice daily and or placebo. A total of 227 patients completed the study. The primary endpoint was walking speed (in feet per second) as measured by the Timed 25-foot Walk (T25W), using a responder analysis. A significantly greater proportion of patients taking Ampyra were responders compared to patients taking placebo: 42.9% vs. 9.3%, respectively. The increased response rate was observed across all four major types of MS disease course. During the double-blind treatment period, a significantly greater proportion of patients taking Ampyra 10 mg twice daily had increases in walking speed of at least 10%, 20%, or 30% from baseline, compared to placebo.

    Side Effects

    Adverse events associated with the use of Ampyra may include, but are not limited to, the following:

    • Urinary tract infection
    • Insomnia
    • Dizziness
    • Headache
    • Nausea
    • Asthenia
    • Back pain
    • Balance disorder
    • Multiple sclerosis relapse
    • Paresthesia
    • Nasopharyngitis
    • Constipation
    • Dyspepsia
    • Pharyngolaryngeal pain

    Mechanism of Action

    Ampyra (dalfampridine) is a potassium channel blocker, available in a 10 mg tablet strength. Each tablet contains 10 mg dalfampridine, formulated as an extended release tablet for twice-daily oral administration. The mechanism by which dalfampridine exerts its therapeutic effect has not been fully elucidated.

    Additional Information

    For additional information regarding Ampyra or multiple sclerosis, please visit the Ampyra web page.

    Approval Date: 2010-01-01
    Date Created: 2010-01-29 12:00:00
    Company Name: Acorda
    Back to Listings

    Upcoming Events

    • 16Dec

      Master the Regulatory Pathway for Cell & Gene Therapy Submissions: Strategies for Successful BLAs

    Featured Products

    • Regenerative-medicine-steps-to-accelerate-development-pdf

      Regenerative Medicine: Steps to Accelerate Development — PDF

    • Clinical-trial-agreements-a-guide-to-key-words-and-phrases-pdf

      Clinical Trial Agreements: A Guide to Key Words and Phrases — PDF

    Featured Stories

    • Ich_logo

      ICH Overhauls 22-Year-Old Clinical Studies Guideline

    • Survey_chart2019

      Sponsors, CROs Doing Better, Sites Say, But More Work Is Needed

    • China-360x240

      U.S. Tops List of Trial Startups With China Making Progress in Phase 1

    • Phoneapp-360x240

      Device Apps Present Unique Risks in Trials

    New!

    2019 Site Survey Reports

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing